CNNM3
geneOn this page
Also known as SLC70A3
Summary
CNNM3 (cyclin and CBS domain divalent metal cation transport mediator 3, HGNC:104) is a protein-coding gene on chromosome 2q11.2, encoding Metal transporter CNNM3 (Q8NE01). Probable metal transporter.
Predicted to enable transmembrane transporter activity. Predicted to be involved in magnesium ion homeostasis. Located in membrane.
Source: NCBI Gene 26505 — RefSeq curated summary.
At a glance
- GWAS associations: 4
- Clinical variants (ClinVar): 153 total
- MANE Select transcript:
NM_017623
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:104 |
| Approved symbol | CNNM3 |
| Name | cyclin and CBS domain divalent metal cation transport mediator 3 |
| Location | 2q11.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | SLC70A3 |
| Ensembl gene | ENSG00000168763 |
| Ensembl biotype | protein_coding |
| OMIM | 607804 |
| Entrez | 26505 |
Gene structure
Transcript identifiers
Ensembl transcripts: 10 — 7 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined
ENST00000305510, ENST00000377060, ENST00000465224, ENST00000480035, ENST00000494595, ENST00000867797, ENST00000947262, ENST00000947263, ENST00000947264, ENST00000947265
RefSeq mRNA: 2 — MANE Select: NM_017623
NM_017623, NM_199078
CCDS: CCDS2025, CCDS2026
Canonical transcript exons
ENST00000305510 — 8 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001160895 | 96828567 | 96828700 |
| ENSE00001160902 | 96828099 | 96828195 |
| ENSE00001160909 | 96827731 | 96827900 |
| ENSE00001160920 | 96825058 | 96825201 |
| ENSE00001853337 | 96816268 | 96817502 |
| ENSE00003520896 | 96828996 | 96829134 |
| ENSE00003530570 | 96826833 | 96826982 |
| ENSE00003844105 | 96832552 | 96835382 |
Expression profiles
Bgee: expression breadth ubiquitous, 250 present calls, max score 95.34.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.0165 / max 63.2175, expressed in 1683 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 21490 | 7.6482 | 1680 |
| 21492 | 0.3683 | 215 |
Top tissues by expression
285 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| gastrocnemius | UBERON:0001388 | 95.34 | gold quality |
| muscle of leg | UBERON:0001383 | 94.68 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 94.39 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 94.39 | gold quality |
| cerebellar cortex | UBERON:0002129 | 94.26 | gold quality |
| right uterine tube | UBERON:0001302 | 94.19 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 94.18 | gold quality |
| cerebellum | UBERON:0002037 | 93.44 | gold quality |
| ventricular zone | UBERON:0003053 | 92.82 | gold quality |
| cardia of stomach | UBERON:0001162 | 91.16 | gold quality |
| pylorus | UBERON:0001166 | 91.12 | gold quality |
| body of pancreas | UBERON:0001150 | 91.10 | gold quality |
| sural nerve | UBERON:0015488 | 90.55 | gold quality |
| left ovary | UBERON:0002119 | 90.22 | gold quality |
| body of uterus | UBERON:0009853 | 90.16 | gold quality |
| tibial nerve | UBERON:0001323 | 90.11 | gold quality |
| nipple | UBERON:0002030 | 89.93 | gold quality |
| right lobe of liver | UBERON:0001114 | 89.92 | gold quality |
| right ovary | UBERON:0002118 | 89.72 | gold quality |
| fundus of stomach | UBERON:0001160 | 89.62 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 89.50 | gold quality |
| pancreas | UBERON:0001264 | 88.97 | gold quality |
| ganglionic eminence | UBERON:0004023 | 88.88 | gold quality |
| mucosa of stomach | UBERON:0001199 | 88.84 | gold quality |
| islet of Langerhans | UBERON:0000006 | 88.83 | gold quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 88.80 | gold quality |
| pituitary gland | UBERON:0000007 | 88.68 | gold quality |
| endocervix | UBERON:0000458 | 88.62 | gold quality |
| cortical plate | UBERON:0005343 | 88.53 | gold quality |
| body of stomach | UBERON:0001161 | 88.30 | gold quality |
Single-cell (SCXA)
Detected in 3 experiment(s), a significant marker in 2.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-5061 | yes | 240.85 |
| E-ANND-3 | yes | 8.78 |
| E-MTAB-6142 | no | 36.50 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
150 targeting CNNM3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-518D-5P | 100.00 | 67.51 | 979 |
| HSA-MIR-518E-5P | 100.00 | 67.66 | 954 |
| HSA-MIR-518F-5P | 100.00 | 67.51 | 979 |
| HSA-MIR-519A-5P | 100.00 | 67.66 | 954 |
| HSA-MIR-519B-5P | 100.00 | 67.66 | 954 |
| HSA-MIR-519C-5P | 100.00 | 67.66 | 954 |
| HSA-MIR-520C-5P | 100.00 | 67.51 | 979 |
| HSA-MIR-522-5P | 100.00 | 67.66 | 954 |
| HSA-MIR-523-5P | 100.00 | 67.66 | 954 |
| HSA-MIR-526A-5P | 100.00 | 67.51 | 979 |
| HSA-MIR-4673 | 100.00 | 66.64 | 1490 |
| HSA-MIR-4668-3P | 100.00 | 68.74 | 2635 |
| HSA-MIR-450A-1-3P | 100.00 | 69.33 | 1837 |
| HSA-MIR-3613-3P | 100.00 | 76.36 | 7965 |
| HSA-MIR-4510 | 100.00 | 66.60 | 2050 |
| HSA-MIR-6127 | 100.00 | 66.76 | 2188 |
| HSA-MIR-6129 | 100.00 | 66.46 | 2080 |
| HSA-MIR-6130 | 100.00 | 66.69 | 2012 |
| HSA-MIR-6133 | 100.00 | 66.48 | 2064 |
| HSA-MIR-6758-5P | 100.00 | 66.21 | 1470 |
| HSA-MIR-6856-5P | 100.00 | 65.47 | 1298 |
| HSA-MIR-6798-5P | 100.00 | 65.77 | 699 |
| HSA-MIR-4455 | 100.00 | 65.48 | 1587 |
| HSA-MIR-3667-3P | 99.99 | 67.17 | 1636 |
| HSA-MIR-4645-5P | 99.98 | 65.81 | 1284 |
| HSA-MIR-6825-5P | 99.96 | 69.81 | 3431 |
| HSA-MIR-4267 | 99.96 | 66.53 | 2368 |
| HSA-MIR-548AT-5P | 99.96 | 70.83 | 2666 |
| HSA-MIR-96-5P | 99.95 | 72.80 | 2140 |
| HSA-MIR-185-3P | 99.95 | 67.01 | 1743 |
Literature-anchored findings (GeneRIF, showing 4)
- This study determined the first crystal structures of the cyclic nucleotide-binding homology (CNBH) domain domains of CNNM2 and CNNM3 at 2.6 and 1.9 A resolutions. (PMID:30341174)
- A FRET-based screening method to detect potential inhibitors of the binding of CNNM3 to PRL2. (PMID:32733084)
- CNN3 in glioma: The prognostic factor and a potential immunotherapeutic target. (PMID:34797350)
- CNNM proteins selectively bind to the TRPM7 channel to stimulate divalent cation entry into cells. (PMID:34928937)
Cross-species orthologs
7 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| ENSDARG00000099568 | ||
| mus_musculus | Cnnm3 | ENSMUSG00000001138 |
| rattus_norvegicus | Cnnm3 | ENSRNOG00000016032 |
| drosophila_melanogaster | uex | FBGN0262124 |
| caenorhabditis_elegans | WBGENE00011260 | |
| caenorhabditis_elegans | WBGENE00016343 | |
| caenorhabditis_elegans | WBGENE00016879 |
Paralogs (3): CNNM1 (ENSG00000119946), CNNM2 (ENSG00000148842), CNNM4 (ENSG00000158158)
Protein
Protein identifiers
Metal transporter CNNM3 — Q8NE01 (reviewed: Q8NE01)
Alternative names: Ancient conserved domain-containing protein 3, Cyclin-M3
All UniProt accessions (1): Q8NE01
UniProt curated annotations — full annotation on UniProt →
Function. Probable metal transporter.
Subcellular location. Cell membrane.
Tissue specificity. Widely expressed. Expressed at higher level in heart and spleen.
Miscellaneous. Shares weak sequence similarity with the cyclin family, hence its name. However, it has no cyclin-like function in vivo.
Similarity. Belongs to the ACDP family.
Isoforms (3)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q8NE01-1 | 1 | yes |
| Q8NE01-2 | 2 | |
| Q8NE01-3 | 3 |
RefSeq proteins (2): NP_060093, NP_951060 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000644 | CBS_dom | Domain |
| IPR002550 | CNNM | Domain |
| IPR044751 | Ion_transp-like_CBS | Domain |
| IPR045095 | ACDP | Family |
| IPR046342 | CBS_dom_sf | Homologous_superfamily |
Pfam: PF00571, PF25562
UniProt features (57 total): strand 16, helix 14, sequence conflict 7, turn 5, transmembrane region 4, domain 3, modified residue 2, splice variant 2, chain 1, glycosylation site 1, region of interest 1, compositionally biased region 1
Structure
Experimental structures (PDB)
7 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 6DFD | X-RAY DIFFRACTION | 1.9 |
| 6WUR | X-RAY DIFFRACTION | 2.88 |
| 5K23 | X-RAY DIFFRACTION | 2.96 |
| 5K22 | X-RAY DIFFRACTION | 3 |
| 5K25 | X-RAY DIFFRACTION | 3.05 |
| 5TSR | X-RAY DIFFRACTION | 3.19 |
| 6MN6 | X-RAY DIFFRACTION | 3.36 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q8NE01-F1 | 67.63 | 0.19 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (2): 661, 700
Glycosylation sites (1): 73
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 116 (showing top):
FISCHER_G1_S_CELL_CYCLE, FOXO1_01, WANG_RESPONSE_TO_BEXAROTENE_UP, FREAC3_01, ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN, GOBP_MONOATOMIC_ION_HOMEOSTASIS, GOBP_TRANSMEMBRANE_TRANSPORT, GOBP_HOMEOSTATIC_PROCESS, GOBP_CHEMICAL_HOMEOSTASIS, chr2q11, GOMF_TRANSPORTER_ACTIVITY, FOXO3_01, GOBP_MAGNESIUM_ION_HOMEOSTASIS, KASLER_HDAC7_TARGETS_1_UP, FEVR_CTNNB1_TARGETS_DN
GO Biological Process (3): monoatomic ion transport (GO:0006811), magnesium ion homeostasis (GO:0010960), transmembrane transport (GO:0055085)
GO Molecular Function (2): transmembrane transporter activity (GO:0022857), protein binding (GO:0005515)
GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| transport | 2 |
| monoatomic cation homeostasis | 1 |
| inorganic ion homeostasis | 1 |
| cellular process | 1 |
| transporter activity | 1 |
| transmembrane transport | 1 |
| binding | 1 |
| membrane | 1 |
| cell periphery | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
954 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| CNNM3 | PTP4A2 | Q12974 | 962 |
| CNNM3 | H7C2H4 | H7C2H4 | 853 |
| CNNM3 | P0DN79 | P0DN79 | 834 |
| CNNM3 | SLC41A1 | Q8IVJ1 | 672 |
| CNNM3 | NIPAL3 | Q6P499 | 605 |
| CNNM3 | NIPAL2 | Q9H841 | 595 |
| CNNM3 | NIPAL1 | Q6NVV3 | 593 |
| CNNM3 | TRPM6 | Q9BX84 | 593 |
| CNNM3 | NIPAL4 | Q0D2K0 | 583 |
| CNNM3 | FAHD2B | Q6P2I3 | 571 |
| CNNM3 | NIPA2 | Q8N8Q9 | 553 |
| CNNM3 | FAM178B | Q8IXR5 | 541 |
| CNNM3 | SLC41A3 | Q96GZ6 | 515 |
| CNNM3 | TRPM7 | Q96QT4 | 502 |
| CNNM3 | SLC41A2 | Q96JW4 | 498 |
IntAct
317 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| CNNM3 | FHL3 | psi-mi:“MI:0915”(physical association) | 0.780 |
| FHL3 | CNNM3 | psi-mi:“MI:0915”(physical association) | 0.780 |
| CNNM3 | MDFI | psi-mi:“MI:0915”(physical association) | 0.760 |
| CNNM3 | KRTAP5-9 | psi-mi:“MI:0915”(physical association) | 0.720 |
| KRTAP10-8 | CNNM3 | psi-mi:“MI:0915”(physical association) | 0.720 |
| CNNM3 | KRTAP10-9 | psi-mi:“MI:0915”(physical association) | 0.720 |
| KRTAP5-9 | CNNM3 | psi-mi:“MI:0915”(physical association) | 0.720 |
| KRTAP10-9 | CNNM3 | psi-mi:“MI:0915”(physical association) | 0.720 |
| PTP4A2 | PTP4A3 | psi-mi:“MI:0914”(association) | 0.640 |
| CANX | PGRMC1 | psi-mi:“MI:0914”(association) | 0.570 |
| CCNDBP1 | CNNM3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| KRTAP2-3 | CNNM3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| KRTAP10-5 | CNNM3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CNNM3 | CBY2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| PNMA1 | CNNM3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| LZTS2 | CNNM3 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CNNM3 | CCNDBP1 | psi-mi:“MI:0915”(physical association) | 0.560 |
BioGRID (278): CNNM3 (Two-hybrid), CNNM3 (Two-hybrid), CNNM3 (Two-hybrid), CNNM3 (Two-hybrid), USHBP1 (Two-hybrid), KRTAP3-2 (Two-hybrid), LZTS2 (Two-hybrid), KRTAP2-4 (Two-hybrid), SPERT (Two-hybrid), KRTAP10-9 (Two-hybrid), KRTAP10-5 (Two-hybrid), KRTAP10-8 (Two-hybrid), CNNM3 (Affinity Capture-MS), CNNM3 (Two-hybrid), KRTAP4-12 (Two-hybrid)
ESM2 similar proteins: A4FV98, A5PK51, A6NDG6, E1BE10, O00587, O35595, O95294, P60487, Q12788, Q17QS4, Q1JPJ0, Q2T9S4, Q2TBI8, Q32NY4, Q3T063, Q3ZBF9, Q501J2, Q5E9V4, Q5F4B1, Q5IS64, Q5SUV1, Q5T9C9, Q6AYG0, Q6AYR8, Q6XQN1, Q6XQN6, Q6ZMM2, Q80US4, Q8BNV1, Q8BZG5, Q8CC86, Q8IZ69, Q8N9H8, Q8NE01, Q8R2H9, Q8TCT1, Q8VCA8, Q8VD52, Q969S8, Q96AZ1
Diamond homologs: A0A0B7P9G0, A0A131MCZ8, A0JPA0, A3QM97, A8EZU0, A8F2M1, A8GPR9, A8GTI4, A8GUH1, O05961, P0C588, Q0GA42, Q12296, Q1RGX2, Q32NY4, Q3TWN3, Q4UK99, Q4V3C7, Q54318, Q57368, Q5U2P1, Q67XQ0, Q68W10, Q69ZF7, Q6P4Q7, Q8NE01, Q8RY60, Q8VZI2, Q92GI2, Q9GYL2, Q9H8M5, Q9LTD8, Q9NRU3, Q9USJ3, Q9ZQR4, Q9ZVS8, Q9CM13, Q9LK65, O05241, O07585
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 80 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Keratinization | 21 | 23.4× | 6e-22 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| regulation of alternative mRNA splicing, via spliceosome | 5 | 21.8× | 9e-04 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
153 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 138 |
| Likely benign | 3 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1385 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 2:96817498:GCGAG:G | donor_gain | 1.0000 |
| 2:96825053:CACA:C | acceptor_loss | 1.0000 |
| 2:96825054:ACAG:A | acceptor_gain | 1.0000 |
| 2:96825055:CA:C | acceptor_loss | 1.0000 |
| 2:96825056:A:AG | acceptor_gain | 1.0000 |
| 2:96825056:AG:A | acceptor_gain | 1.0000 |
| 2:96825056:AGG:A | acceptor_gain | 1.0000 |
| 2:96825057:G:A | acceptor_loss | 1.0000 |
| 2:96825057:G:GA | acceptor_gain | 1.0000 |
| 2:96825057:GG:G | acceptor_gain | 1.0000 |
| 2:96825057:GGG:G | acceptor_gain | 1.0000 |
| 2:96825057:GGGA:G | acceptor_gain | 1.0000 |
| 2:96825057:GGGAA:G | acceptor_gain | 1.0000 |
| 2:96825197:CTACC:C | donor_gain | 1.0000 |
| 2:96825198:TACC:T | donor_gain | 1.0000 |
| 2:96825199:ACC:A | donor_gain | 1.0000 |
| 2:96825200:CC:C | donor_gain | 1.0000 |
| 2:96825202:G:GG | donor_gain | 1.0000 |
| 2:96826826:A:AG | acceptor_gain | 1.0000 |
| 2:96826827:T:G | acceptor_gain | 1.0000 |
| 2:96826830:TAG:T | acceptor_loss | 1.0000 |
| 2:96826831:A:AG | acceptor_gain | 1.0000 |
| 2:96826831:AG:A | acceptor_gain | 1.0000 |
| 2:96826832:G:A | acceptor_loss | 1.0000 |
| 2:96826832:G:GG | acceptor_gain | 1.0000 |
| 2:96826832:GG:G | acceptor_gain | 1.0000 |
| 2:96826832:GGA:G | acceptor_gain | 1.0000 |
| 2:96826832:GGAGA:G | acceptor_gain | 1.0000 |
| 2:96826931:G:GG | donor_gain | 1.0000 |
| 2:96826979:CGAG:C | donor_loss | 1.0000 |
AlphaMissense
4467 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 2:96817455:T:A | V393D | 0.999 |
| 2:96817457:T:C | F394L | 0.999 |
| 2:96817459:C:A | F394L | 0.999 |
| 2:96817459:C:G | F394L | 0.999 |
| 2:96817494:T:C | F406S | 0.999 |
| 2:96825072:G:C | A414P | 0.999 |
| 2:96825073:C:A | A414D | 0.999 |
| 2:96825136:T:A | V435D | 0.999 |
| 2:96817482:T:A | V402D | 0.998 |
| 2:96825079:T:A | V416E | 0.998 |
| 2:96825129:G:C | G433R | 0.998 |
| 2:96827856:T:G | Y549D | 0.998 |
| 2:96827890:T:C | L560P | 0.998 |
| 2:96828106:T:A | V566D | 0.998 |
| 2:96828138:T:C | F577L | 0.998 |
| 2:96828140:T:A | F577L | 0.998 |
| 2:96828140:T:G | F577L | 0.998 |
| 2:96828153:T:C | F582L | 0.998 |
| 2:96828155:C:A | F582L | 0.998 |
| 2:96828155:C:G | F582L | 0.998 |
| 2:96828166:G:A | G586E | 0.998 |
| 2:96829011:T:G | Y646D | 0.998 |
| 2:96817320:G:C | R348P | 0.997 |
| 2:96817326:C:A | P350Q | 0.997 |
| 2:96817457:T:A | F394I | 0.997 |
| 2:96817485:T:C | L403P | 0.997 |
| 2:96817493:T:C | F406L | 0.997 |
| 2:96817495:C:A | F406L | 0.997 |
| 2:96817495:C:G | F406L | 0.997 |
| 2:96825070:T:C | L413P | 0.997 |
dbSNP variants (sampled 300 via entrez): RS1000127740 (2:96815099 T>C,G), RS1000182020 (2:96815421 A>G), RS1000354178 (2:96821384 A>G), RS1000403109 (2:96827091 C>A,G,T), RS1000640626 (2:96822717 C>A,T), RS1000641398 (2:96829921 T>G), RS1000680235 (2:96818490 A>G,T), RS1001044115 (2:96835061 C>A), RS1001078352 (2:96817877 GA>G), RS1001140620 (2:96828367 C>T), RS1001240015 (2:96822106 G>A), RS1001296341 (2:96833230 G>A,C), RS1001412002 (2:96833413 G>A,C,T), RS1001469297 (2:96817721 G>C), RS1001471407 (2:96829679 A>G)
Disease associations
OMIM: gene MIM:607804 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
4 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST000824_20 | Erectile dysfunction and prostate cancer treatment | 6.000000e-06 |
| GCST008103_13 | Bipolar disorder | 4.000000e-09 |
| GCST008362_203 | Birth weight | 3.000000e-09 |
| GCST008363_28 | Offspring birth weight | 5.000000e-06 |
EFO canonical traits (2, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004344 | birth weight |
| EFO:0005939 | parental genotype effect measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
31 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Valproic Acid | affects cotreatment, increases expression, increases methylation | 2 |
| Cyclosporine | decreases expression | 2 |
| Aflatoxin B1 | decreases expression, increases methylation | 2 |
| FR900359 | affects phosphorylation | 1 |
| triphenyl phosphate | affects expression | 1 |
| sodium arsenite | increases abundance, increases expression | 1 |
| perfluorooctanoic acid | decreases expression | 1 |
| benzo(e)pyrene | increases methylation | 1 |
| coumarin | increases phosphorylation | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| perfluorooctane sulfonic acid | increases expression | 1 |
| (+)-JQ1 compound | increases expression | 1 |
| Temozolomide | increases expression | 1 |
| Acetaminophen | affects response to substance | 1 |
| Air Pollutants | increases abundance, affects expression | 1 |
| Arsenic | increases abundance, increases expression | 1 |
| Benzo(a)pyrene | affects methylation | 1 |
| Caffeine | affects phosphorylation | 1 |
| Diazinon | increases methylation | 1 |
| Hydralazine | affects cotreatment, increases expression | 1 |
| Methapyrilene | increases methylation | 1 |
| Ozone | affects expression, increases abundance | 1 |
| Selenomethionine | affects expression | 1 |
| Smoke | decreases expression | 1 |
| Tobacco Smoke Pollution | decreases expression | 1 |
| Tretinoin | decreases expression | 1 |
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | decreases expression | 1 |
| Okadaic Acid | decreases expression | 1 |
| Copper Sulfate | decreases expression | 1 |
| tert-Butylhydroperoxide | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): bipolar disorder, erectile dysfunction, prostate carcinoma